- Home
- AENT vs SCPH Comparison
AENT vs SCPH Comparison
Compare AENT & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AENT
- SCPH
- Stock Information
- Founded
- AENT 1990
- SCPH 2013
- Country
- AENT United States
- SCPH United States
- Employees
- AENT N/A
- SCPH N/A
- Industry
- AENT Durable Goods
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- AENT Consumer Discretionary
- SCPH Health Care
- Exchange
- AENT Nasdaq
- SCPH Nasdaq
- Market Cap
- AENT 148.0M
- SCPH 173.6M
- IPO Year
- AENT N/A
- SCPH 2017
- Fundamental
- Price
- AENT $3.09
- SCPH $2.62
- Analyst Decision
- AENT
- SCPH Strong Buy
- Analyst Count
- AENT 0
- SCPH 3
- Target Price
- AENT N/A
- SCPH $14.00
- AVG Volume (30 Days)
- AENT 56.2K
- SCPH 480.5K
- Earning Date
- AENT 05-08-2025
- SCPH 05-13-2025
- Dividend Yield
- AENT N/A
- SCPH N/A
- EPS Growth
- AENT N/A
- SCPH N/A
- EPS
- AENT 0.13
- SCPH N/A
- Revenue
- AENT $1,070,804,000.00
- SCPH $36,332,000.00
- Revenue This Year
- AENT $4.77
- SCPH $114.00
- Revenue Next Year
- AENT N/A
- SCPH $77.45
- P/E Ratio
- AENT $22.42
- SCPH N/A
- Revenue Growth
- AENT N/A
- SCPH 167.28
- 52 Week Low
- AENT $1.10
- SCPH $1.94
- 52 Week High
- AENT $11.57
- SCPH $5.65
- Technical
- Relative Strength Index (RSI)
- AENT 45.51
- SCPH 51.56
- Support Level
- AENT $2.66
- SCPH $2.50
- Resistance Level
- AENT $3.20
- SCPH $2.64
- Average True Range (ATR)
- AENT 0.49
- SCPH 0.24
- MACD
- AENT 0.05
- SCPH 0.06
- Stochastic Oscillator
- AENT 69.29
- SCPH 91.41
About AENT Alliance Entertainment Holding Corporation
Alliance Entertainment Holding Corp is a top-tier distributor of music, movies, and consumer electronics. It offers products consisting of vinyl records, compact discs, DVDs, Blu-rays, and video games. The company serves customers of every size, providing a suite of services to resellers and retailers around the world.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.